Investment Rating - The report maintains a "Recommended" rating for the company [4] Core Views - The company achieved a revenue of 7.99 billion yuan in H1 2024, a year-on-year decrease of 10.8%, but turned a profit with a net profit of 280 million yuan, compared to a loss in the previous year [1] - In Q2 2024, the company reported a revenue of 4.22 billion yuan, down 16.9% year-on-year but up 11.6% quarter-on-quarter, with a net profit of 220 million yuan, marking a significant recovery with a 311.8% increase from the previous quarter [1] - The feed business saw a volume increase of 7.6% year-on-year, with revenue of 2.84 billion yuan, down 5.6% year-on-year, while the animal health business remained stable with a revenue of 500 million yuan, up 12.0% year-on-year [1] - The pig farming segment turned profitable, with sales of 1.401 million pigs in H1 2024, a 7.0% increase year-on-year, and an average selling price of 14.4 yuan/kg, up 2.0% year-on-year [1] Financial Performance Summary - The company’s cash reserves reached 2.86 billion yuan as of H1 2024, a 6.7% increase quarter-on-quarter, indicating a recovery in financial stability [2] - The net cash flow from operating activities in Q2 2024 was 1.11 billion yuan, turning positive from a negative position, reflecting improved profitability in pig farming [2] - The company’s debt-to-asset ratio stood at 51.1% as of H1 2024, a decrease of 2.6 percentage points, indicating a relatively low level of financial risk [2] Earnings Forecast - The company is expected to achieve net profits of 698 million yuan, 1.132 billion yuan, and 1.548 billion yuan for the years 2024, 2025, and 2026 respectively, with corresponding EPS of 0.51 yuan, 0.83 yuan, and 1.13 yuan [3][2] - The projected PE ratios for the same years are 13, 8, and 6 times respectively, indicating a favorable valuation outlook [2]

公司点评报告 ·农林牧渔行业 Q2 业绩持续向好,养殖成本改善中 核心观点 2024年8月28日 | --- | --- | --- | --- | |-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - In the first half of 2024, the company achieved total operating revenue of 799,304.35 million yuan, a decrease of 10.82% compared to the same period last year [2] - The net profit attributable to shareholders was 27,668.29 million yuan, an increase of 161.86% year-on-year [2] - The feed business sold 134.94 million tons, a year-on-year increase of 7.6%, but sales revenue decreased by 5.63% due to price fluctuations in raw materials [2][3] Business Segment Analysis - The pig farming business had a total of 140.14 million pigs slaughtered, an increase compared to last year [2] - The animal vaccine business maintained stable sales and profitability, with revenue of 50,000.14 million yuan, a year-on-year increase of 12.04% [3] - The plant protein and corn storage businesses saw a decline in revenue due to a downward trend in raw material prices [3] Cost Management - The complete cost of pig farming in Q2 was 15.15 yuan/kg, which decreased to 14.75 yuan/kg in July [3] - The company plans to improve production efficiency and management levels to further reduce costs [4] Future Outlook - The company is focusing on upgrading hardware facilities for epidemic prevention, particularly in Henan and Gansu regions [4] - The animal vaccine business is expected to see improved gross margins as market conditions for pig farming become more favorable in the second half of the year [4]

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2024-052 天康生物股份有限公司 2024 年半年度募集资金存放与实际使用情况专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 根据《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》（证 监会公告[2022]15 号）和《深圳证券交易所上市公司自律监管指引第 1 号—主板上市 公司规范运作》、《深圳证券交易所上市公司自律监管指引第 2 号—公告格式》等有 关规定，天康生物股份有限公司（以下简称"公司"）将截至 2024 年 6 月 30 日的募 集资金存放与实际使用情况说明如下： 一、募集资金基本情况 1、实际募集资金金额、资金到位情况 经中国证券监督管理委员会《关于核准天康生物股份有限公司非公开发行股票的 批复》（证监许可[2021]1771 号）核准，核准天康生物股份有限公司非公开发行不 超过 322,540,482 股新股。本次非公开发行实际发行数量 277,449,664 股，发行价 格为人民币 7.45 元/股，募集资金总额为人民币 206,700 万元，扣 ...

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2024-050 天康生物股份有限公司 第八届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 同意该项议案的票数为 7 票；反对票 0 票；弃权票 0 票； 天康生物股份有限公司（以下简称"公司"）第八届董事会第十九次会议通 知于 2024 年 8 月 16 日以书面专人送达和电子邮件等方式发出，并于 2024 年 8 月 27 日（星期二）上午 10：30 分以现场结合通讯表决方式召开，应到会董事 7 人，实到会董事 7 人（其中以通讯表决方式出席会议的董事为董海英、陈克峰、 屈勇刚）。公司部分监事及其他高级管理人员列席了会议。会议符合《公司法》、 《公司章程》的规定，会议合法有效。本次会议由董事长张杰先生主持，经与会 人员认真审议，形成如下决议： 一、议案审议情况 （一）审议并通过公司《关于聘任高级管理人员的议案》； 经公司总经理成辉先生提名，公司董事会同意聘任黄海滨、郭运江、郑东生 为公司副总经理，任期自本次董事会审议通过之日起至本届董事会届满之日止。 （简历附 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 7,993,043,517.91, a decrease of 10.82% compared to CNY 8,963,149,801.46 in the same period last year[10]. - Net profit attributable to shareholders of the listed company reached CNY 276,682,923.94, a significant increase of 161.86% from a loss of CNY 447,288,636.14 in the previous year[10]. - The basic earnings per share improved to CNY 0.20, compared to a loss of CNY 0.33 per share in the same period last year, marking a 160.61% increase[10]. - The net cash flow from operating activities was CNY 773,337,830.28, down 50.38% from CNY 1,558,665,809.03 in the previous year[10]. - Total assets at the end of the reporting period were CNY 16,652,519,915.24, a slight decrease of 0.59% from CNY 16,751,659,614.41 at the end of the previous year[10]. - The net assets attributable to shareholders of the listed company increased by 3.14% to CNY 6,612,173,142.34 from CNY 6,410,600,615.20 at the end of the previous year[10]. - The weighted average return on net assets improved to 4.24%, up 10.03% from -5.79% in the same period last year[10]. - The company achieved total operating revenue of CNY 799,304.35 million, a decrease of 10.82% year-on-year[18]. - Operating profit increased by 165.82% year-on-year to CNY 31,734.37 million, while total profit rose by 158.93% to CNY 29,379.73 million[18]. - The company reported a total initial investment in futures contracts of 27.55 million yuan, with a fair value change of -7.9764 million yuan during the reporting period[33]. Revenue Breakdown - The company sold 134.94 million tons of feed, a year-on-year increase of 7.6%, despite a 5.63% decline in sales revenue to CNY 283,788.72 million due to falling feed prices[18]. - The company reported a 11.17% increase in sales revenue from pig farming to CNY 287,605.15 million, with a year-on-year increase of 7.00% in the number of pigs sold, totaling 1.4014 million[18]. - Sales revenue from the plant protein and oil processing business decreased by 43.17% to CNY 73,310.50 million due to fluctuating raw material prices[18]. - The corn storage business saw a 45.85% decline in sales revenue to CNY 75,728.95 million, attributed to high initial corn prices and reduced purchasing plans[18]. - The revenue from the pig breeding industry chain was approximately ¥2.88 billion, representing an increase of 11.17% compared to ¥2.59 billion in the previous year[23]. - The feed industry revenue decreased by 5.63% to approximately ¥2.84 billion from ¥3.01 billion year-on-year[23]. - The veterinary medicine sector's revenue increased by 12.04% to approximately ¥500 million, up from ¥446 million in the previous year[23]. Research and Development - Research and development investment increased by 54.79% to approximately ¥155.29 million, reflecting the company's commitment to enhancing R&D capabilities[22]. - The company has established R&D centers in Xinjiang, Shanghai, and Jiangsu, with over 400 R&D personnel and 29 national new veterinary drug certificates[22]. - The ongoing animal vaccine research and production project in Suzhou has accumulated actual investment of approximately 891 million RMB, with a completion rate of 93.38%[31]. - Research and development expenses increased to CNY 154,290,133.74, up 56.4% from CNY 98,737,400.70 in the first half of 2023, indicating a focus on innovation[93]. Environmental Compliance - The company has established a robust biosecurity management system to mitigate risks associated with African swine fever, which remains a significant threat to the livestock industry[44]. - The company has implemented various environmental protection standards, including GB 13271-2014 for particulate matter and GB 21907-2008 for wastewater[53]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[51]. - The company has established emergency response plans for environmental incidents at multiple subsidiaries, including Xinjiang Kuitun Tiankang Plant Protein Co., Ltd. and Henan Tiankang Hongzhan Food Co., Ltd.[56]. - The company emphasizes the protection of shareholder and creditor rights, ensuring compliance with contractual obligations[60]. Corporate Governance - The company has established a complete internal control system and governance structure to ensure effective management and compliance[58]. - The company has committed to maintaining its independence in operations, assets, finance, and business[62]. - The company has not experienced any major changes in project feasibility[40]. - The company has not reported any issues or other situations regarding the use and disclosure of raised funds[40]. - The company has not changed any fundraising projects during the reporting period[41]. Shareholder Information - The company did not distribute cash dividends or issue bonus shares for the first half of 2024[50]. - The company held three temporary shareholder meetings in April 2024, with participation rates of 30.04%, 30.11%, and 30.45% respectively[48]. - The largest shareholder, Xinjiang Production and Construction Corps State-owned Assets Management Co., Ltd., holds 21.58% of the shares, equating to 294,580,922 shares[76]. - The total number of common shareholders at the end of the reporting period is 58,224[76]. - The report confirms that there are no related party relationships or concerted actions among the shareholders[78]. Future Outlook - The company plans to continue expanding its market presence and invest in new product development[102]. - The company is actively pursuing new strategies for market expansion and potential acquisitions to drive growth[109]. - The company plans to invest $20 million in sustainability initiatives over the next two years[195]. - The company provided an optimistic outlook, projecting a revenue growth of 20% for the next fiscal year[196]. Financial Position - The company's total liabilities decreased from CNY 8,836,902,688.33 to CNY 8,501,486,397.07, a decrease of approximately 3.79%[89]. - The company's total equity reached CNY 7,647,320,348.45, compared to CNY 7,548,762,716.86 in the same period last year[92]. - The company's cash and cash equivalents at the end of the reporting period amounted to approximately 2.86 billion RMB, accounting for 17.19% of total assets[26]. - The company reported a total comprehensive income loss of -40,833,921.20 CNY during the current period[100]. Risk Management - The company has detailed its risks and countermeasures in the management discussion section of the report[2]. - The company has implemented strict risk control measures for its futures hedging operations, including adherence to internal control systems and risk monitoring by a dedicated risk control team[34]. - The company has not engaged in speculative derivative investments during the reporting period[35].

| | 天 康 畜 牧 科 技 有限公司 | 全资子公司 | 其他应收款 | 331,986.14 | 271,422.43 | 250,432.51 | 352,976.06 | 借款 | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 其他关联方及其附属 | | | | | | | | | | | 企业 | | | | | | | | | | | 总计 | - | - | - | 435,118.28 | 607,141.61 | 586,476.88 | 455,783.01 | | - | 法定代表人：张杰 主管会计工作的负责人：耿立新 会计机构负责人：王潇 天康生物股份有限公司 2024 年 半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 非经营性资金占用 资金占用方名 称 占用方与上 市公司的关 联关系 上市公司核算 的会计科目 2024 年期初 占用资金余 额 2024 年 1-6 月 占用累计发生 金额（不含利 息） 2024 年 1-6 月 占用资金的利 息（如有） 2024年1 ...

一、议案审议情况 （一）审议并通过公司《2024 年半年度报告全文及摘要》的议案；（内容详 见刊登于 2024 年 8 月 29 日本公司指定信息披露报纸《证券时报》上的《天康生 物股份有限公司 2024 年半年度报告摘要》<公告编号：2024-051>和在巨潮资讯 网 www.cninfo.com.cn 上披露的《天康生物股份有限公司 2024 年半年度报告全 文》） 同意该项议案的票数为 3 票；反对票 0 票；弃权票 0 票； 天康生物 证券代码：002100 证券简称：天康生物 公告编号：2024-053 天康生物股份有限公司 第八届监事会第十一次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 天康生物股份有限公司（以下简称"公司"）第八届监事会第十一次会议通 知于 2024 年 8 月 16 日以书面专人送达和电子邮件方式发出，并于 2024 年 8 月 27 日（星期二）上午 12 时以现场结合通讯表决方式召开，公司 3 名监事均参加 了会议（其中以通讯表决方式出席会议的监事为张涛）。董事会秘书列席了会议， 符合《公司法》的有关规定，会 ...

天康生物 2024 年第四次临时股东大会法律意见书 新疆星河律师事务所 新疆星河律师事务所 关于天康生物股份有限公司 1 天康生物 2024 年第四次临时股东大会法律意见书 新疆星河律师事务所 法律意见书 星河证股字[2024]第 008 号 致：天康生物股份有限公司 新疆星河律师事务所（以下简称"本所"）接受天康生物股份有限公 司（以下简称"公司"）委托，指派律师出席公司 2024 年第四次临时股 东大会（以下简称"本次会议"），并根据《中华人民共和国证券法》（以 下简称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公 司法》"）、《上市公司股东大会规则》（以下简称"《规则》"）、《深 圳证券交易所股票上市规则》（以下简称"《上市规则》"）和《天康生 物股份有限公司章程》（以下简称"《公司章程》"）的相关规定，就公 司本次会议的召集与召开程序、出席会议人员资格、召集人资格、会议表 决程序和表决结果的合法性等有关法律问题出具法律意见书。 为出具本法律意见书，本所律师对公司本次会议所涉及的有关事项进 行了审查，查阅了本所律师认为出具本法律意见书所必须查阅的文件，并 对有关问题进行了必要的核查和验证。 ...

天康生物 证券代码：002100 证券简称：天康生物 公告编号：2024-049 天康生物股份有限公司 2024 年第四次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 现场会议时间：2024 年 8 月 12 日上午 10：30 网络投票时间：2024 年 8 月 12 日，其中，通过深圳证券交易所交易系统进 行网络投票的具体时间为 2024 年 8 月 12 日上午 9:15—9:25，9:30—11:30 和下 午 13:00-15:00；通过深圳证券交易所互联网投票系统进行网络投票的具体时间 为 2024 年 8 月 12 日上午 9：15 至下午 15:00 任意时间。 （二）会议召开地点：新疆乌鲁木齐市高新区长春南路 528 号天康企业大 厦 11 楼公司 4 号会议室。 （三）会议召开方式：现场投票与网络投票相结合的方式。 （四）会议召集人：公司董事会 重要提示： 1、本次股东大会无增加、变更、否决提案的情况； 2、本次股东大会未涉及变更以往股东大会已通过的决议的情况。 一、 会议召开和出席情况 （一）会议召开时间 412,9 ...